IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene CDH5 Ensembl ENSG00000179776 Chromosome 16 Start 64958064 End 64996186
Description Cadherin-5 Precursor (Vascular endothelial cadherin)(VE-cadherin)(7B4 antigen)(CD144 antigen) [Source:UniProtKB/Swiss-Prot;Acc:P33151]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 1764
     Entrez Gene : 1003
     UCSC : uc002eom.3
     GeneCards : 1764
     RefSeq : NM_001795
     CCDS : CCDS10804.1
     Uniprot : P33151
     Interpro : P33151
     OMIM : 601120
     GeneTests : CDH5
     CGAP : CDH5
     PMID : 2059658

< Top >


Experimental Evidence        (help)
Expression Sample Number Method Clinical information PubMed Reference
down - RT-PCR- 21528670 Tumori. 2011 Jan-Feb;97(1):86-94.

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  37196_at  -2.30  1.94e-32  7.19e-30  -2.81  3.86e-18  2.33e-16
 HG_U133A  204677_at  -2.50  6.29e-117  9.56e-114  -1.99  5.11e-60  1.38e-59
 HG_U133_Plus2  204677_at  -2.17  1.95e-46  9.02e-44  -2.56  9.29e-31  4.69e-29
 Stanford  7644  -1.81  2.71e-6  2.73e-4  -2.39  2.08e-7  3.35e-5
 Agilent_HS_21.6K  16836  -0.16  1.19e-7  3.87e-6  -0.17  2.97e-7  5.54e-6

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  204677_at  0.35  4.47e-1  9.14e-1  -0.44  2.58e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 37196_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 204677_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 204677_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 7644    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 16836    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
ve-cadherin human tumor These data provide evidence of a role for PECAM-1 in human tumor angiogenesis (independent of VE-cadherin) and suggest that during angiogenesis PECAM-1 participates in adhesive and/or signaling phenomena required for the motility of endothelial cells and/ 11940533 Human
ve-cadherin tumor angiogenesis We have shown previously that a monoclonal antibody (BV13) to VE-cadherin not only inhibits the formation of vascular tubes during tumor angiogenesis but also disrupts adherens junctions of normal vasculature with a concomitant increase in vascular permea 11980651 Human
ve-cadherin tumor Our data also suggest that antibody E4G10 recognizes VE-cadherin epitopes that are only accessible on endothelial cells forming new adherens junctions, such as in angiogenic tumor vasculature. 11980651 Human
ve-cadherin tumor Inhibition of VE-cadherin by the blocking monoclonal antibody (mAb) BV13 inhibited angiogenesis and tumor growth in vivo. 12130501 Human
ve-cadherin tumour Most recently, we have found that some of these antioxidants may prevent tumour growth by inhibiting angiogenesis via suppression of interleukin 8 and modulation of the cell junction molecule, VE-cadherin. 12133197 Human
ve-cadherin tumor Hence, inhibitors of VE-cadherin adhesive properties may constitute a tool to prevent tumor neovascularization. 11238107 Human
vascular endothelial cadherin angiosarcoma Angiosarcoma of the scalp: absence of vascular endothelial cadherin in primary and metastatic lesions. 11251578 Human
ve-cadherin melanoma Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. 11416160 Human
ve-cadherin melanoma Down-regulation of VE-cadherin expression in the aggressive melanoma cells abrogated their ability to form vasculogenic networks and directly tested the hypothesis that VE-cadherin is critical in melanoma vasculogenic mimicry. 11416160 Human
ve-cadherin tumors P-cadherin was found focally in two RCCs only, while VE-cadherin was present on stromal vessel endothelium in five tumors, showing no differences with regard to cell type, growth pattern, tumor grade or TNM status. 11504373 Human
ve-cadherin tumor P-cadherin was found focally in two RCCs only, while VE-cadherin was present on stromal vessel endothelium in five tumors, showing no differences with regard to cell type, growth pattern, tumor grade or TNM status. 11504373 Human
ve-cadherin cancer Recently, we also demonstrated that these dietary antioxidants may have a preventive role in cancer, potentially through the suppression of angiogenesis by inhibiting interleukin-8 production and the cell junction molecule VE-cadherin. 11795514 Human
ve-cadherin tumour We report that following tumour cell (MDA MB231 cells) adherence to the HUVECs, there was a rapid (within 5 min) redistribution of VE-cadherin, resulting in its transient loss from regions of endothelial cell-cell contact. 10402488 Human
ve-cadherin tumour It was further shown that the overall expression of VE-cadherin did not change, however, the amount of alpha- and beta-catenins coprecipitated with VE-cadherin markedly decreased after 5 min of tumour cell adhesion to the HUVECs. 10402488 Human
ve-cadherin tumour Immunoprobing of these samples with anti-phosphotyrosine antibodies demonstrated that the tyrosine phosphorylation of VE-cadherin was significantly increased following 5 min of tumour cell adhesion. 10402488 Human
ve-cadherin tumour Together, these results suggest that the adhesion of tumour cells to HUVEC promotes the redistribution of VE-cadherin from interendothelial adherens junctions, an effect that may be attributed to the increase in tyrosine phosphorylation of members of the 10402488 Human
ve-cadherin tumor After adhering to the surface of endothelial cells, tumor cells must penetrate the endothelial junction, which contains high concentrations of the cell adhesion molecules VE-cadherin and PECAM-1. 9840805 Human
ve-cadherin melanoma Despite the disappearance of VE-cadherin from the retracting endothelial junction, heterotypic contacts between the tumor cell and its surrounding endothelial cells show a high concentration of pan-cadherin staining, suggesting that transmigration of mela 9840805 Human
ve-cadherin tumor Despite the disappearance of VE-cadherin from the retracting endothelial junction, heterotypic contacts between the tumor cell and its surrounding endothelial cells show a high concentration of pan-cadherin staining, suggesting that transmigration of mela 9840805 Human
ve cadherin epithelioid sarcomas METHODS AND RESULTS: Seven epithelioid sarcomas were immunostained by a polyclonal antibody that detects all cadherin subtypes and by monoclonal antibodies that detect epithelial cadherin (E-cadherin) and vascular-endothelial cadherin (VE cadherin). 9839166 NA
ve-cadherin melanoma Cadherins, including VE-cadherin, but not N-cadherin, were enriched in contacts between EC, whereas N-cadherin, but not VE-cadherin, was found in contacts between melanoma cells. 9415377 Human
ve-cadherin melanoma During the early stages of diapedesis, EC located below the attached melanoma cells decreased in height and VE-cadherin disappeared from the EC contact located underneath the melanoma cell. 9415377 Human
ve-cadherin melanoma Despite the absence of both VE-cadherin and N-cadherin, other members of the cadherin family were present in the heterotypic contacts between EC and melanoma cells. 9415377 Human
ve-cadherin breast adenocarcinoma We show that human breast adenocarcinoma cells (MCF-7), but not normal human mammary epithelial cells, induce a rapid endothelial cell (EC) dissociation which correlates with the loss of VE-cadherin expression at the site of tumor cell-EC contact and with 9434630 Human
ve-cadherin tumor We show that human breast adenocarcinoma cells (MCF-7), but not normal human mammary epithelial cells, induce a rapid endothelial cell (EC) dissociation which correlates with the loss of VE-cadherin expression at the site of tumor cell-EC contact and with 9434630 Human
ve-cadherin tumor Immunoprecipitations and Western blot analysis demonstrate that the overall expression of VE-cadherin and vinculin as well as the composition of the VE-cadherin/catenins complex are not affected by tumor cells while the tyrosine phosphorylation status of 9434630 Human
vascular endothelial cadherin tumor angiogenesis This review concentrates on angiogenic growth factors including vascular endothelial growth factor, angiopoietins, platelet derived endothelial growth factor, and basic fibroblast growth factor, proteases, adhesion molecules including vascular endothelial 12539173 Human
ve-cadherin angiosarcoma VE-cadherin is highly expressed in endothelial cells of haemangiomas and is decreased, but still detectable, in some cases of haemangionendothelioma and angiosarcoma. 7891227 Human
ve-cadherin tumour Tumour angiogenesis was assessed by immunohistochemical staining of primary tissue sections using VE-cadherin (an endothelial cell specific cell-cell adhesion molecule). 12807719 Human
ve-cadherin melanoma tumor Vasculogenic mimicry (VM) describes the unique ability of highly aggressive melanoma tumor cells to express endothelial cell-associated genes (such as EphA2 and VE-cadherin) and form vasculogenic-like networks when cultured on a three-dimensional matrix. 12941789 Human
ve-cadherin tumour Tumour growth and mRNA expression of human and murine VEGF and murine VE-Cadherin in the tumours were measured. 12820432 Human
ve-cadherin tumours Tumour growth and mRNA expression of human and murine VEGF and murine VE-Cadherin in the tumours were measured. 12820432 Human
vascular endothelial cadherin nsclc This review concentrates on angiogenic growth factors including vascular endothelial growth factor, angiopoietins, platelet derived endothelial growth factor, and basic fibroblast growth factor, proteases, adhesion molecules including vascular endothelial 12539173 Human
vascular endothelial cadherin brain tumor The brain tumor ECs differed from normal brain ECs morphologically and by their expression and distribution of specific markers (that is, vascular endothelial cadherin [VE-cadherin] and CD31). 15871513 Human
ve-cadherin glioblastomas In glioblastomas endothelial proliferations represent the majority of vascular structures; they were positive for endothelial markers (vWF, CD31, VE-cadherin) and negative for macrophage markers (CD68, PAM-1). 8803595 Human
ve-cadherin primary tumor The reduction of tumor growth was accompanied by reduction of angiogenesis, as demonstrated by the staining of VE-cadherin in primary tumor tissues. 14519655 Human
ve-cadherin tumor The reduction of tumor growth was accompanied by reduction of angiogenesis, as demonstrated by the staining of VE-cadherin in primary tumor tissues. 14519655 Human
ve-cadherin tumor angiogenesis Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. 15205354 Human
ve-cadherin cancer Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. 15205354 Human
ve-cadherin cancer By means of a quantitative reverse transcription-PCR approach, we measured VE-cadherin (VE-C), Tie-2, vascular endothelial growth factor receptor 2 and CD133 RNA in the blood of 14 healthy controls, 3 pregnant women, and 84 newly diagnosed (or relapsed) c 15205354 Human
ve-cadherin breast tumor We define and validate the up-regulated expression of VE-cadherin and osteonectin in breast tumor vasculature. 15520192 Human
ve-cadherin breast cancer Although our results support E-cadherin as the TSG in invasive lobular carcinoma, they argue against the candidacy of E2F-4, CTCF, TRF2, P-cadherin, Ksp-cadherin and VE-cadherin as TSGs in breast cancer. 15609312 Human
ve-cadherin invasive lobular carcinoma Although our results support E-cadherin as the TSG in invasive lobular carcinoma, they argue against the candidacy of E2F-4, CTCF, TRF2, P-cadherin, Ksp-cadherin and VE-cadherin as TSGs in breast cancer. 15609312 Human
ve-cadherin melanoma A PLC inhibitor, U73122 was shown to significantly diminish [Ca2+]i response and reduce the occurrence of melanoma cell-induced VE-cadherin reorganization. 15769649 Human
ve-cadherin melanoma However, melanoma cell-associated VE-cadherin breakdown was not sensitive to Ly294002, an inhibitor of phosphatidylinositol-3-kinase (PI3K), whereas inhibition of PI3K resulted in a reduction of melanoma cell transmigration. 15769649 Human
ve-cadherin human breast cancer Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. 15810954 Human
ve-cadherin breast cancer We hypothesized that VE-cadherin may be a useful marker for assessing microvessels and angiogenesis in human breast cancer and sought to determine whether a correlation exists between levels of VE-cadherin, angiogenic markers factor VIII and platelet endo 15810954 Human
ve-cadherin human breast cancer We hypothesized that VE-cadherin may be a useful marker for assessing microvessels and angiogenesis in human breast cancer and sought to determine whether a correlation exists between levels of VE-cadherin, angiogenic markers factor VIII and platelet endo 15810954 Human
ve-cadherin breast cancer METHODS AND RESULTS: Frozen sections from breast cancer primary tumours (tumour n = 114, background n = 30) were immunostained with VE-cadherin, factor VIII and PECAM-1 antibodies and microvessel number was assessed. 15810954 Human
ve-cadherin tumour METHODS AND RESULTS: Frozen sections from breast cancer primary tumours (tumour n = 114, background n = 30) were immunostained with VE-cadherin, factor VIII and PECAM-1 antibodies and microvessel number was assessed. 15810954 Human
ve-cadherin primary tumours METHODS AND RESULTS: Frozen sections from breast cancer primary tumours (tumour n = 114, background n = 30) were immunostained with VE-cadherin, factor VIII and PECAM-1 antibodies and microvessel number was assessed. 15810954 Human
ve-cadherin tumour VE-cadherin immunostaining showed a significant difference in microvessel number in tumour compared with background. 15810954 Human
ve-cadherin tumour Q-PCR revealed elevated levels of VE-cadherin and PECAM-1 in tumour samples compared with background tissue and in patients with a poor prognosis, as determined by the Nottingham Prognostic Index. 15810954 Human
ve-cadherin ductal carcinomas Both VE-cadherin and PECAM-1 had significantly reduced expression in lobular compared with ductal carcinomas: there was no difference with factor VIII. 15810954 Human
ve-cadherin tumour The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. 15735710 Human
ve-cadherin ks Furthermore, immunofluorescence analysis showed that beta-catenin and VE-cadherin staining changed from a uniform distribution along the membrane of controls to a diffuse pattern with gap formation in PAF-treated KS cells. 15855650 Human
ve-cadherin brain tumor The brain tumor ECs differed from normal brain ECs morphologically and by their expression and distribution of specific markers (that is, vascular endothelial cadherin [VE-cadherin] and CD31). 15871513 Human
ve-cadherin tumor Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. 15701713 Human
ve-cadherin tumor We have studied 3 monoclonal antibodies (mAbs) against murine VE-cadherin that inhibit angiogenesis and tumor growth. 15701713 NA
ve-cadherin tumor Cadherin expression inversely correlates with tumor malignancy and the endothelial specific VE-cadherin is low or absent in angiosarcomas, suggesting an inhibitory role for this protein in tumor progression. 15968386 Human
ve-cadherin angiosarcomas Cadherin expression inversely correlates with tumor malignancy and the endothelial specific VE-cadherin is low or absent in angiosarcomas, suggesting an inhibitory role for this protein in tumor progression. 15968386 Human
ve-cadherin malignancy Cadherin expression inversely correlates with tumor malignancy and the endothelial specific VE-cadherin is low or absent in angiosarcomas, suggesting an inhibitory role for this protein in tumor progression. 15968386 Human
ve-cadherin vascular tumors In this paper we report that PmyT VE-cadherin null (VEC null) endothelial cells form larger vascular tumors in nude mice when injected subcutaneously as compared to isogenic VE-cadherin positive (VEC pos) cells. 15968386 Mouse
ve-cadherin tumors Overall, these data strongly suggest that downregulation of VE-cadherin in endothelial tumors may have important consequences for tumor growth and bleeding complications. 15968386 Mouse
ve-cadherin tumor Overall, these data strongly suggest that downregulation of VE-cadherin in endothelial tumors may have important consequences for tumor growth and bleeding complications. 15968386 Mouse
ve-cadherin tumor In addition, we analyzed whether blockade of vascular endothelial (VE)-cadherin as a different antiangiogenic target could also inhibit glioblastoma angiogenesis and growth.Experimental Designs: Nude mice who received intracerebral glioblastoma xenografts 16000592 Human
ve-cadherin glioblastoma EXPERIMENTAL DESIGNS: Nude mice who received intracerebral glioblastoma xenografts were treated using monoclonal antibodies against VEGFR-2 (DC101), EGFR (C225), and VE-cadherin (E4G10) either alone or in different combinations. 16000592 Human
ve-cadherin tumor angiogenesis The anti-VE-cadherin monoclonal antibody E4G10 was a weaker inhibitor of tumor angiogenesis and growth than DC101, and also caused a weaker increase in tumor cell invasion. 16000592 Human
ve-cadherin tumor The anti-VE-cadherin monoclonal antibody E4G10 was a weaker inhibitor of tumor angiogenesis and growth than DC101, and also caused a weaker increase in tumor cell invasion. 16000592 Human
ve-cadherin glioma CONCLUSIONS: Inhibition of angiogenesis achieved by blocking either VEGFR-2 or VE-cadherin can cause increased glioma cell invasion in an orthotopic model. 16000592 Mouse
ve-cadherin carcinoma Anchorage of carcinoma cells led to the rupture of endothelial integrity, as revealed by the formation of holes in the monolayer and by the disappearance of the interendothelial VE-Cadherin network. 15914035 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.